18F-DCFPyL PET-CT Scan and Prostate Cancer

Prostate Cancer Adenocarcinoma Clinical Trial

Official title:

A Novel 18F-DCFPyL PET-CT Scan for Diagnosis and Management of Prostate Cancer

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT03852654
• Other study ID #: Jafari0001
• Status: Recruiting
• Phase: Phase 2/Phase 3
• Start date: July 22, 2018
• Est. completion date: June 30, 2020

Study information

• Verified date: February 2019
• Source: VA Greater Los Angeles Healthcare System
• Contact: Jafari Lida, M.D.
• Phone: 310 268 3583
• Email: lida.jafari[@]va.gov
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Primary Objective:

The primary objective of this study is to assess the efficacy of 18F-DCFPyL PET-CT for initial staging of prostate cancer in Veterans compared to conventional imaging (99mTc-MDP bone scan and Diagnostic CT or MRI). The primary clinical endpoint of our study is the percent of Veterans with prostate cancer in which the 18F-DCFPyL PET-CT identifies M1 disease at initial staging.

Secondary Objectives:

Frequency of the change in primary treatment plan after initial staging.

Description:

This is a single arm Phase II clinical trial in Veterans with prostate cancer, no prior local therapy, who are at risk of having metastatic disease (PSA greater than 10, or Gleason Score greater than or equal to 4+3, or clinical stage greater than or equal to T2c). Veterans who are planned to undergo or have recently undergone conventional, routine care initial staging scans for prostate cancer (99mTc-MDP or NaF PET bone scan and diagnostic CT or MRI of pelvis) will also receive a 18F-DCFPyL PET-CT scan. The primary endpoint is the percent of Veterans with prostate cancer in which the 18F-DCFPyL PET-CT scan identifies evidence of M1 disease at initial staging.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 170
• Est. completion date: June 30, 2020
• Est. primary completion date: December 30, 2019
• Accepts healthy volunteers: No
• Gender: Male
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

1. Age = 18 years and male.

2. Ability to understand the study and the willingness to sign a written informed consent document.

3. Histologically confirmed adenocarcinoma of the prostate.

4. PSA greater than 10, or Gleason =4+3, or clinical stage greater than or equal toT2c.

5. Plan to undergo (or have already undergone) routine care initial systemic staging with conventional imaging for prostate cancer.

6. Eastern Cooperative Oncology Group (ECOG) Performance score of 0 to 2.

7. No prior local therapy for prostate cancer (i.e., prostatectomy, radiotherapy, etc.).

8. Willing to comply with the procedural requirements of this protocol.

Exclusion Criteria:

1. Serious or uncontrolled co-existent non-malignant disease, including active and uncontrolled infection.

2. The subject has a condition or situation that, in the investigator's opinion, may put the subject at significant risk, may confound the study results, or may interfere significantly with subject's participation in the study.

3. Primary small cell carcinoma of the prostate.

4. Participation in this study significantly delay the scheduled standard of care therapy.

5. Weighs greater than 350 lbs., or unable to fit within the imaging gantry.

6. The subject undergone prior local therapy for prostate cancer (i.e. prostatectomy, radiotherapy, etc.).

7. Currently receiving androgen deprivation therapy (ADT) or anti-androgen? Previous use of ADT is allowed IF the subject has been off ADT or anti-androgen for 3 months or more.

Related Conditions & MeSH terms

• Adenocarcinoma
• Prostate Cancer Adenocarcinoma
• Prostatic Neoplasms

Intervention

Drug:
• 18F-DCFPyL
Subjects with biopsy proven prostate cancer, no prior local therapy, and: PSA = 10 ng/dl, or Gleason Sum = 4+3, or clinical stage =cT2c Staging by 99mTc-MDP or NaF PET bone scan, and Diagnostic CT (pelvis) or MRI will undergo 18F DCFPyL PET CT scan.

Locations

Country	Name	City	State
United States	VA Greater Los Angeles	Los Angeles	California

Sponsors (2)

Lead Sponsor	Collaborator
Lida Jafari	University of California, Los Angeles

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	the percent of Veterans with prostate cancer in which the 18F-DCFPyL PET-CT identifies M1 disease at initial staging		120 days